CoChat

First Trimester Prenatal Treatment and Molecular Genetic Diagnosis of Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency)*

SPEISER, PHYLLIS W., LAFORGIA, NICOLA, KATO, KOJI, PAREIRA, JUDITH, KHAN, RAFIYA, YANG, SOO YOUNG, WHORWOOD, CHRISTOPHER, WHITE, PERRIN C., ELIAS, SHERMAN, SCHRIOCK, ELIZABETH, SCHRIOCK, ELDON, SIMPSON, JOE LEIGH, TASLIMI, MARK, NAJJAR, JENNIFER, MAY, STEVEN, MILLS, GARY, CRAWFORD, CHRISTOPHER, NEW, MARIA I. · 1990 · The Journal of Clinical Endocrinology & Metabolism
Cited by 128

The DOI matches its Crossref record.

Abstract

Prenatal treatment of pregnancies at risk for congenital adrenal hyperplasia due to 21-hydroxylase deficiency was carried out in conjunction with chorionic villus sampling (CVS) in the first trimester for analysis of restriction fragment length polymorphisms. Fourteen families of a total of 49 families at risk for this disease elected to undergo both prenatal treatment and diagnosis via CVS. Dexamethasone administration to the pregnant woman was initiated at a mean gestational age of 7 weeks (range, 4-10 weeks) before testing to determine whether the fetus was affected with 21-hydroxylase deficiency, and CVS was performed at a gestational age of 8-10 weeks. Two affected female fetuses were identified by molecular genetic techniques among this group; neonatal physical examination demonstrated amelioration of the degree of genital ambiguity compared with both nonprenatally treated older sisters with 21-hydroxylase deficiency. The duration of unnecessary prenatal dexamethasone treatment for unaffected or male fetuses was substantially reduced in the CVS group compared with that in a cohort of 8 prenatally treated pregnancies in which amniocentesis was performed in the early second trimester. There were no major morbidities observed in the treated pregnancies. Postnatal confirmation of CVS diagnosis was obtained in all cases in which DNA from an affected sibling was available for comparative analysis with the DNA from chorionic villus tissue. We conclude based on these data that the benefit/risk ratio is favorable for prenatal administration of dexamethasone in pregnancies at risk for 21-hydroxylase deficiency. Treatment should be initiated during the first trimester in conjunction with diagnosis by CVS/molecular genetic techniques. Long term postnatal surveillance is recommended for all offspring of dexamethasone-treated pregnancies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jcem-70-4-838

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 128

Metadata

Authors
SPEISER, P. W., LAFORGIA, N., KATO, K., PAREIRA, J., KHAN, R., YANG, S. Y., WHORWOOD, C., WHITE, P. C., ELIAS, S., SCHRIOCK, E., SCHRIOCK, E., SIMPSON, J. L., TASLIMI, M., NAJJAR, J., MAY, S., MILLS, G., CRAWFORD, C., & NEW, M. I.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
1990-04
Volume
70
Issue
4
Pages
838-848
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2077415800
Cited by
128
References
0
FWCI
4.05
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: First Trimester Prenatal Treatment and Molecular Genetic Diagnosis of Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency)*. https://app.cochat.ai/papers/10.1210/jcem-70-4-838
The paper
SPEISER, P. W., LAFORGIA, N., KATO, K., PAREIRA, J., KHAN, R., YANG, S. Y., WHORWOOD, C., WHITE, P. C., ELIAS, S., SCHRIOCK, E., SCHRIOCK, E., SIMPSON, J. L., TASLIMI, M., NAJJAR, J., MAY, S., MILLS, G., CRAWFORD, C., & NEW, M. I. (1990). First Trimester Prenatal Treatment and Molecular Genetic Diagnosis of Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency)*. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jcem-70-4-838

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.